1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-08-12 am EDT
53.38 EUR   +0.76%
08/09GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
PU
08/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 - Form 6-K
PU
08/08Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galapagos NV acquired CellPoint B.V. from ND Capital and others for approximately €230 million.

06/21/2022 EDT

Galapagos NV (ENXTAM:GLPG) entered into agreement to acquire CellPoint B.V. from ND Capital and others for approximately €230 million on June 21, 2022. All-cash transaction includes payment of an upfront amount of €125 million for CellPoint, with an additional €100 million to be paid upon achievement of certain milestones. The transactions have been fully executed and the acquisitions were consummated earlier today. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to CellPoint. Rebecca Kuijpers-Zimmerman, Roel Meers, Oren Livne, and Els Janssens of Baker McKenzie acted as legal advisor to Galapagos NV. Galapagos NV (ENXTAM:GLPG) completed the acquisition of CellPoint B.V. from ND Capital and others on June 21, 2022


© S&P Capital IQ 2022
All news about GALAPAGOS NV
08/09GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
PU
08/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 ..
PU
08/08Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
CI
08/08Galapagos receives transparency notification from FMR LLC
GL
08/08Galapagos receives transparency notification from FMR LLC
AQ
08/08RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
08/08GALAPAGOS NV : Crossing thresholds
CO
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 528 M 541 M 541 M
Net income 2022 -153 M -157 M -157 M
Net cash 2022 3 538 M 3 628 M 3 628 M
P/E ratio 2022 1 091x
Yield 2022 -
Capitalization 3 509 M 3 597 M 3 597 M
EV / Sales 2022 -0,06x
EV / Sales 2023 0,52x
Nbr of Employees 1 305
Free-Float 73,7%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 53,38 €
Average target price 60,56 €
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV7.64%3 596
MODERNA, INC.-32.35%67 212
LONZA GROUP AG-23.32%46 073
IQVIA HOLDINGS INC.-14.23%45 135
SEAGEN INC.12.57%32 099
ALNYLAM PHARMACEUTICALS, INC.35.27%27 533